ACIU · Company research
AC Immune SA (ACIU): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. - Stock Titan | Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions - Simply Wall Street | AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 24, 2026 | neutral | 0 | 0.6 |
| After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan | After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha | AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 20, 2026 | neutral | 0 | 0.6 |
| AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance | AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 Yahoo Finance | View source ↗ | Yahoo Finance | Aug 20, 2026 | neutral | 0 | 0.6 |
| $ACIU stock is up 13% today. Here's what we see in our data. - Quiver Quantitative | $ACIU stock is up 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 11, 2026 | neutral | 0 | 0.6 |
| ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’ - Stocktwits | ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’ Stocktwits | View source ↗ | Stocktwits | Aug 11, 2026 | neutral | 0 | 0.6 |
| AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Simply Wall Street | AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| ACIU Forecast — Price Target — Prediction for 2027 - TradingView | ACIU Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance | Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Apr 9, 2026 | neutral | 0 | 0.6 |
| ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - Yahoo Finance | ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Apr 9, 2026 | neutral | 0 | 0.6 |
| Why AC Immune Stock Zoomed Almost 15% Higher Today - The Motley Fool | Why AC Immune Stock Zoomed Almost 15% Higher Today The Motley Fool | View source ↗ | The Motley Fool | Apr 7, 2026 | neutral | 0 | 0.6 |
| AC IMMUNE SA (ACIU) Stock - Gotrade | AC IMMUNE SA (ACIU) Stock Gotrade | View source ↗ | Gotrade | Feb 3, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Dec 20, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.